Phenomenal Guidelines On How Regulation Could Challenge Traditional Marketing

As it’s estimated that the marketing of pharmaceutical products accounts for up to $25 billion of spending each year, there is a lot at stake for healthcare professionals everywhere. In recent times, there’s been much talk about the methodology used by pharmaceutical companies and the tactics they utilise as their sales force members contact and try and convince professionals. Indeed, some advocate that the industry should be more tightly regulated and the U.S. Congress has been strongly urged to take an in depth look at how business is conducted in this arena. With these dynamics in the background, the pharmaceutical company must take a highly focused and professional approach to the very way that it acts and how it reaches the people responsible for buying products and generating revenues enabling it to survive in the first place.

Certain countries around the World have been quick to introduce legislation and restrictions governing how pharmaceutical companies may interact with professionals. Some countries such as Australia, for example, have established certain codes of conduct, setting standards for ethical marketing and insisting that member organisations comply with the requirements.

Pharmaceuticals sales executives will spend a lot of time involved in what is known as “detailing,” by visiting front line professionals and explaining how the product might work, giving market suggestions, likely product availability, how it should be dosed, side effects that could be expected and other details. Their communication skills must be absolutely excellent and sales executives must be able to systematically break down barriers that may have been built up over years of suspicion. The sales executive has a pivotal role to play in helping to give the professional supplemental educational information. The pharmaceutical company must pay a great deal of attention to these methods of marketing.

If additional new regulations or restrictions develop in the near future, this would put even more emphasis on the need for effective marketing by the organisation. A company should engage pharmaceutical consulting firms due to the fact that they have direct experience and can as such help to train and educate the sales force so that they do not stumble at a vital time, make mistakes or negatively interact with professionals and spoil any potential gains.

Disclosure may be called for in future, detailing hospitality provided or suggested, levels of assistance given or gifts related and a clear indication of the style and type of education imparted. Not only will it be necessary for the sales executive to be highly educated in the product itself, fully understanding of restrictions and implications, but the executive must also be fully able to market to their highest ability.

Generally, pharmaceutical consultants will focus a great deal of their available time on striving to balance training between methods and product awareness. Time management is an essential skill required and staff must be trained to make best use of it, just as traditional marketing skills must be a point of focus and any latest developments or new legal requirements included. In most cases, pharma consulting outsources these important areas, enabling company chiefs to focus on other core areas of concern. With ineffective marketing, reputations can be compromised and there can be other implications, including problems with regulations and authorities; consultants must steer the organisation carefully.

Alan Gillies is the Director of L2L Consulting, an elite pharmaceutical consultancy firm which specialises in Strategy Development and Implementation Excellence for prestigious multi-national organisations.